{"organizations": [], "uuid": "2f7b1cb56663ab0dfc68238c213cffba85a17c9a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530546?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Fidelity leads oversubscribed $55mm Series C round for Afferent", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Fidelity leads oversubscribed $55mm Series C round for Afferent", "spam_score": 0.0, "site_type": "news", "published": "2015-07-14T02:31:00.000+03:00", "replies_count": 0, "uuid": "2f7b1cb56663ab0dfc68238c213cffba85a17c9a"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530546?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Fidelity leads oversubscribed $55mm Series C round for Afferent", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Fidelity leads oversubscribed $55mm Series C round for Afferent Deal Date: Jul-01-2015 / Deal # 201530546 Executive Summary \nAfferent Pharmaceuticals Inc. (cardiology, respiratory, neurology, and urology targets in C-fiber primary afferent nerves) closed an oversubscribed $55mm Series C round led by new backer Fidelity Management & Research and including other first-time shareholders Jennison Associates, Partner Fund Management, Redmile Group, Tekla Healthcare Investors, Tekla Life Science Investors, and a blue chip investment fund, plus existing investor New Leaf Ventures.", "external_links": [], "published": "2015-07-14T02:31:00.000+03:00", "crawled": "2015-07-14T14:28:48.000+03:00", "highlightTitle": ""}